What's in Formycon AG's pipeline?

Formycon AG has 3 drugs in our index: 2 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Formycon AG's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/formycon-ag.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Formycon AG — Portfolio Competitive Intelligence Brief

Formycon AG pipeline: 2 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
AHZANTIVE	AFLIBERCEPT-MRBB	marketed			Other
NUFYMCO	RANIBIZUMAB-LEYK	marketed			Other
FYB206	FYB206	phase 3	VEGF/PlGF inhibitor biosimilar	VEGF-A, VEGF-B, PlGF	Ophthalmology

Therapeutic area mix

Other · 2
Ophthalmology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Formycon AG:

Cite this brief

Drug Landscape (2026). Formycon AG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/formycon-ag. Accessed 2026-05-14.